Monitor for Phase 2 trial initiation in Q4 2026 and any future topline data readout, which would be the next major catalyst. No near-term stock-moving event from this update.
Price Chart
Executive Summary
SCYNEXIS announced completion of a Phase 1 study for SCY-770, a first-in-class oral direct AMPK activator for ADPKD, showing favorable safety and tolerability. The Phase 2 proof-of-concept study remains on track to initiate in Q4 2026. This is a routine pipeline update with no new binary catalyst or financial data.
Key Facts
- Phase 1 study of SCY-770 completed in 25 healthy participants across three cohorts, evaluating doses up to 750 mg once daily and 500 mg twice daily for seven days.
- SCY-770 was well tolerated with a favorable safety profile; pharmacokinetic data will support Phase 2 dose selection.
- Phase 2 proof-of-concept study in ADPKD patients remains on track to initiate in Q4 2026.
- SCY-770 has Orphan Drug Designation from the FDA for ADPKD.
- ADPKD has only one approved therapy (Jynarque/tolvaptan) with ~$1.5B in U.S. sales in 2024.
- SCY-770 has been evaluated in ~300 participants across multiple trials to date.
Financial Impact
No financial data disclosed; Phase 2 initiation in Q4 2026 is a non-binary milestone.
Risk Factors
- Phase 2 trial may not initiate on schedule or may fail to meet endpoints.
- SCY-770 faces competition from Jynarque and potential future ADPKD therapies.
- SCYNEXIS is a clinical-stage biotech with no revenue from SCY-770; cash runway and financing risk exist.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3375347 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | Press Release | $3.81 | awaiting T+5 | — | $3.80 (−0.26%) |
Oct 6, 2026 21d ago | Press Release | $4.84 $3.99 | ▼ −17.56% | ▼ −17.42% | $3.80 (−21.49%) |
Sep 28, 2026 29d ago | Press Release | $4.62 $5.03 | ▲ +8.87% | ▲ +7.67% | $3.80 (−17.75%) |
Sep 22, 2026 5w ago | 8-K | $4.86 $4.66 | ▼ −4.12% | ▼ −2.93% | $3.80 (−21.81%) |
Sep 10, 2026 6w ago | 8-K | $4.70 $4.45 | ▼ −5.32% | ▼ −4.82% | $3.80 (−19.15%) |
Jun 26, 2026 17w ago | 8-K | $3.87 $4.73 | ▲ +22.22% | ▲ +20.83% | $3.80 (−1.81%) |
May 22, 2026 22w ago | 8-K | $5.45 $5.33 | ▼ −2.17% | ▼ −3.25% | $3.80 (−30.25%) |
May 11, 2026 24w ago | Press Release | $6.24 $5.26 | ▲ +15.77% | ▲ +15.17% | $3.80 (+39.10%) |
Apr 20, 2026 27w ago | 8-K | $8.48 $7.89 | ▼ −6.98% | ▼ −8.06% | $3.80 (−55.19%) |
Mar 31, 2026 30w ago | Press Release | $7.34 $7.97 | ▲ +8.62% | ▲ +4.67% | $3.80 (−48.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers